Waters Corporation (NYSE: WAT) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | S&P 500 | P/E | 100.95 | EPS (ttm) | 4.01 | Insider Own | 0.66% | Shs Outstand | 74.79M | Perf Week | -0.25% |
| Market Cap | 30.28B | Forward P/E | 24.53 | EPS next Y | 16.50 | Insider Trans | -0.63% | Shs Float | 74.70M | Perf Month | -1.69% |
| Enterprise Value | 34.94B | PEG | 9.18 | EPS next Q | 4.01 | Inst Own | - | Short Float | 4.87% | Perf Quarter | 9.07% |
| Income | 166.00M | P/S | 6.52 | EPS this Y | 263.44% | Inst Trans | - | Short Ratio | 3.96 | Perf Half Y | 35.10% |
| Sales | 4.64B | P/B | 1.99 | EPS next Y | 13.22% | ROA | 0.67% | Short Interest | 3.64M | Perf YTD | 6.58% |
| Book/sh | 203.17 | P/C | 56.17 | EPS next 5Y | 11.00% | ROE | 1.88% | 52W High | 426.21 -5.02% | Perf Year | 30.85% |
| Cash/sh | 7.21 | P/FCF | 76.84 | EPS past 3/5Y | -2.84% 5.18% | ROIC | 1.34% | 52W Low | 282.77 43.16% | Perf 3Y | 44.05% |
| Dividend Est. | - | EV/EBITDA | 39.04 | Sales past 3/5Y | 2.12% 6.00% | Gross Margin | 50.78% | Volatility | 2.64% 2.77% | Perf 5Y | -2.22% |
| Dividend TTM | - | EV/Sales | 7.52 | EPS Y/Y TTM | -62.56% | Oper. Margin | 7.96% | ATR (14) | 12.13 | Perf 10Y | 154.76% |
| Dividend Ex-Date | Nov 26, 1996 | Quick Ratio | 1.29 | Sales Y/Y TTM | 57.00% | Profit Margin | 3.58% | RSI (14) | 50.15 | Recom | 2.57 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.86 | EPS Q/Q | 3.39% | SMA20 | -1.51% | Beta | 1.15 | Target Price | 438.36 |
| Payout | 0.00% | Debt/Eq | 0.57 | Sales Q/Q | 113.36% | SMA50 | 3.01% | Rel Volume | 0.91 | Prev Close | 402.91 |
| Employees | 7,900 | LT Debt/Eq | 0.39 | Earnings | Nov 03 | SMA200 | 12.12% | Avg Volume | 828.43K | Price | 404.81 |
| IPO Date | Nov 17, 1995 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 1.32% 1.40% | Net Debt/EBITDA | 5.26 | Volume | 751,342 | Change | 0.47% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-09-26 | Reiterated | UBS | Neutral | $375 → $490 |
| Aug-27-26 | Upgrade | Piper Sandler | Neutral → Overweight | $400 → $480 |
| Aug-05-26 | Reiterated | Morgan Stanley | Equal Weight | $390 → $430 |
| Aug-05-26 | Reiterated | Deutsche Bank | Hold | $380 → $400 |
| Aug-05-26 | Reiterated | Stifel Nicolaus | $380 → $420 | |
| Aug-05-26 | Reiterated | RBC Capital | Outperform | $435 → $475 |
| Aug-05-26 | Upgrade | TD Cowen | Hold → Buy | |
| Aug-05-26 | Reiterated | Barclays | Overweight | $425 → $460 |
| Aug-05-26 | Reiterated | Evercore ISI Group | Outperform | $410 → $420 |
| Jul-14-26 | Reiterated | Goldman Sachs | Buy | $425 |
Waters Corporation is a global leader in specialized measurement, delivering analytical solutions across Asia, the Americas, and Europe. The company operates through two main divisions: Waters and TA. Under its Waters segment, it engineers, manufactures, sells, and provides support for high and ultra-performance liquid chromatography and mass spectrometry (MS) systems. This includes essential consumables like chromatography columns and comprehensive post-warranty service plans. The TA segment focuses on designing, producing, selling, and servicing instruments for thermal analysis, rheometry, and calorimetry. Additionally, Waters develops and supplies sophisticated software that integrates with both its own instruments and those from other manufacturers. The company's advanced MS technology plays a crucial role in various applications, such as drug discovery and development (including clinical trial assessments), analyzing proteins involved in disease processes, ensuring nutritional safety, and conducting environmental testing. Its thermal analysis, rheometry, and calorimetry instruments are vital for assessing the suitability and stability of a wide range of materials, including fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids. These instruments support diverse sectors like industrial manufacturing, consumer goods, healthcare products, and life science research. Waters' extensive client base spans the life sciences, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental sectors, where its products are instrumental in research and development, quality assurance, and general laboratory operations. Established in 1958, Waters Corporation is headquartered in Milford, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4,644 | 3,165 | 2,958 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 2,286 | 1,337 | 1,200 | — | — | — | — | — | — | |
| Gross Profit | 2,358 | 1,829 | 1,758 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 1,210 | 740 | 690 | — | — | — | — | — | — | |
| Research and Development | 322 | 195 | 183 | — | — | — | — | — | — | |
| Other Operating Expense | 457 | 0 | 59 | — | — | — | — | — | — | |
| Operating Income | 370 | 893 | 826 | — | — | — | — | — | — | |
| Interest Expense | 139 | 70 | 90 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -26 | -69 | 18 | — | — | — | — | — | — | |
| Net Income Before Taxes | 205 | 755 | 755 | — | — | — | — | — | — | |
| Income Taxes | 39 | 112 | 117 | — | — | — | — | — | — | |
| Consolidated Net Income | 166 | 643 | 638 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 166 | 643 | 638 | — | — | — | — | — | — | |
| Net Income | 166 | 643 | 638 | — | — | — | — | — | — | |
| EPS (Recurring) | 4.02 | 10.80 | 10.75 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 4.02 | 10.80 | 10.75 | — | — | — | — | — | — | |
| EPS (Diluted) | 4.01 | 10.76 | 10.71 | — | — | — | — | — | — | |
| EBITDA | 895 | 1,012 | 1,036 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 100.95 | 35.30 | 34.64 | — | — | — | — | — | — | |
| Price To Sales Ratio | 8.54 | 7.20 | 7.40 | — | — | — | — | — | — | |
| Gross Margin | 50.78 | 57.79 | 59.43 | — | — | — | — | — | — | |
| Operating Margin | 7.97 | 28.21 | 27.92 | — | — | — | — | — | — | |
| Net Margin | 3.57 | 20.32 | 21.57 | — | — | — | — | — | — | |
| Shares Outstanding | 98 | 60 | 59 | — | — | — | — | — | — | |
| Market Capitalization | 39,671 | 22,790 | 21,888 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| KUEBLER CHRISTOPHER A | Director | Aug 06 '26 | Option Exercise | 136.43 | 3,626 | 494,695 | 21,434 | Aug 07 |
| KUEBLER CHRISTOPHER A | Director | Aug 06 '26 | Sale | 397.94 | 3,626 | 1,442,930 | 17,808 | Aug 07 |
| Jiang Wei | Director | Mar 16 '26 | Buy | 289.46 | 500 | 144,730 | 3,441 | Mar 18 |
| FEARON RICHARD H | Director | Mar 06 '26 | Buy | 306.34 | 1,000 | 306,340 | 3,302 | Mar 10 |
| KUEBLER CHRISTOPHER A | Director | Nov 05 '25 | Option Exercise | 130.35 | 3,761 | 490,246 | 18,796 | Nov 07 |
| FEARON RICHARD H | Director | May 28 '24 | Buy | 332.90 | 1,000 | 332,900 | 1,653 | May 29 |
| KUEBLER CHRISTOPHER A | Director | May 15 '24 | Option Exercise | 113.88 | 4,000 | 455,520 | 18,716 | May 16 |
| KUEBLER CHRISTOPHER A | Director | May 15 '24 | Sale | 361.64 | 4,000 | 1,446,560 | 14,716 | May 16 |
| BADDOUR LINDA | Director | Mar 13 '24 | Sale | 355.54 | 500 | 177,770 | 2,250 | Mar 14 |
| KUEBLER CHRISTOPHER A | Director | Aug 04 '23 | Option Exercise | 99.22 | 4,000 | 396,880 | 18,382 | Aug 07 |
| KUEBLER CHRISTOPHER A | Director | Aug 04 '23 | Sale | 291.48 | 4,000 | 1,165,920 | 14,382 | Aug 07 |
| VERGNANO MARK P | Director | Feb 28 '23 | Buy | 313.32 | 3,185 | 997,927 | 3,557 | Mar 01 |
| CONARD EDWARD | Director | Nov 30 '22 | Option Exercise | 212.06 | 8,000 | 1,696,500 | 75,283 | Dec 08 |
| CONARD EDWARD | Director | Nov 30 '22 | Sale | 334.70 | 1,059 | 354,447 | 74,224 | Dec 08 |
| KUEBLER CHRISTOPHER A | director: | May 19 '22 | Sale | 328.78 | 4,000 | 1,315,120 | 14,064 | May 23 |